We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMDX Wins Full FDA IDE Approval for Next-Gen OCS ENHANCE Heart Trial
Read MoreHide Full Article
Key Takeaways
TransMedics secured full FDA IDE approval for the OCS ENHANCE Heart trial.
The two-part study will enroll 650 patients, comparing OCS Heart with cold storage.
TMDX shares rose 3.4% in six months, outperforming the industry's 6.9% decline.
TransMedics (TMDX - Free Report) recently announced that it has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its next-generation OCS ENHANCE Heart trial, eliminating a key regulatory milestone and allowing the company to move forward with full trial execution and patient enrollment.
From an investor perspective, the approval meaningfully de-risks the clinical roadmap and strengthens confidence in TransMedics’ long-term growth story, as successful execution could support broader clinical indications, higher utilization of the OCS platform and sustained adoption across heart transplantation over the coming years.
Likely Trend of TMDX Stock Following the News
Following the announcement, the company's shares traded flat at Friday’s market closing. Shares of the company have gained 3.4% in the last six-months period against the industry’s 6.9% decline. The S&P 500 has gained 8.1% in the same time frame.
In the long run, the full FDA IDE approval strengthens TransMedics’ ability to expand the addressable heart transplant market by positioning OCS Heart as not just a preservation tool but a performance-enhancing platform. If the ENHANCE trial demonstrates superior outcomes versus cold storage, it could support label expansion, higher utilization per center and longer transport times, directly translating into more OCS cases and recurring disposables revenue.
Meanwhile, TMDX currently has a market capitalization of $4.44 billion.
Image Source: Zacks Investment Research
More on the OCS ENHANCE Heart Trial
The OCS ENHANCE Heart trial is designed as a two-part, large-scale clinical program aimed at redefining how donor hearts are preserved and optimized prior to transplantation. Part A focuses on evaluating prolonged heart perfusion using the next-generation OCS Heart System, with the goal of maintaining and potentially improving cardiac function during extended preservation times. Part B then moves into a randomized comparison, evaluating outcomes in donation after brain death hearts preserved on OCS versus those stored using traditional static cold storage. With an expected enrollment exceeding 650 patients, the trial is positioned to generate one of the most robust clinical datasets ever assembled in heart transplantation.
From an investment standpoint, the structure of ENHANCE is particularly compelling because it targets standard-criteria donor hearts, not just marginal or high-risk organs. If successful, the trial could meaningfully broaden the clinical use case for OCS Heart by extending preservation windows beyond the current four-hour limit and demonstrating superior outcomes versus cold storage.
Favorable Industry Prospect for TMDX
Per a report by Zion Market Research, the global organ transplantation market size was worth around $18.59 billion in 2023 and is predicted to grow to around $33.32 billion by 2032, at a CAGR of roughly 6.70%.
The organ transplantation market is growing as rising cases of chronic diseases increase the need for transplants, while advances in immunosuppression therapies improve patient outcomes and confidence in surgery. At the same time, innovations in organ preservation technologies are extending organ viability and boosting transplant success rates, supporting broader adoption.
Other News
In January, TMDX announced a long-term lease for its new global headquarters at Assembly Innovation Park and acquired adjacent land to build an integrated campus, underscoring its commitment to accelerating innovation, growth, and the transformation of organ transplant therapy.
TMDX’s Zacks Rank & Stocks to Consider
TMDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and AtriCure (ATRC - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.8% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 13.4% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
AtriCure, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted loss per share of 1 cent, narrower than the Zacks Consensus Estimate by 90.9%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 91.7% for 2026 compared with the industry’s 16.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.1%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
TMDX Wins Full FDA IDE Approval for Next-Gen OCS ENHANCE Heart Trial
Key Takeaways
TransMedics (TMDX - Free Report) recently announced that it has received full and unconditional FDA Investigational Device Exemption (IDE) approval for its next-generation OCS ENHANCE Heart trial, eliminating a key regulatory milestone and allowing the company to move forward with full trial execution and patient enrollment.
From an investor perspective, the approval meaningfully de-risks the clinical roadmap and strengthens confidence in TransMedics’ long-term growth story, as successful execution could support broader clinical indications, higher utilization of the OCS platform and sustained adoption across heart transplantation over the coming years.
Likely Trend of TMDX Stock Following the News
Following the announcement, the company's shares traded flat at Friday’s market closing. Shares of the company have gained 3.4% in the last six-months period against the industry’s 6.9% decline. The S&P 500 has gained 8.1% in the same time frame.
In the long run, the full FDA IDE approval strengthens TransMedics’ ability to expand the addressable heart transplant market by positioning OCS Heart as not just a preservation tool but a performance-enhancing platform. If the ENHANCE trial demonstrates superior outcomes versus cold storage, it could support label expansion, higher utilization per center and longer transport times, directly translating into more OCS cases and recurring disposables revenue.
Meanwhile, TMDX currently has a market capitalization of $4.44 billion.
Image Source: Zacks Investment Research
More on the OCS ENHANCE Heart Trial
The OCS ENHANCE Heart trial is designed as a two-part, large-scale clinical program aimed at redefining how donor hearts are preserved and optimized prior to transplantation. Part A focuses on evaluating prolonged heart perfusion using the next-generation OCS Heart System, with the goal of maintaining and potentially improving cardiac function during extended preservation times. Part B then moves into a randomized comparison, evaluating outcomes in donation after brain death hearts preserved on OCS versus those stored using traditional static cold storage. With an expected enrollment exceeding 650 patients, the trial is positioned to generate one of the most robust clinical datasets ever assembled in heart transplantation.
From an investment standpoint, the structure of ENHANCE is particularly compelling because it targets standard-criteria donor hearts, not just marginal or high-risk organs. If successful, the trial could meaningfully broaden the clinical use case for OCS Heart by extending preservation windows beyond the current four-hour limit and demonstrating superior outcomes versus cold storage.
Favorable Industry Prospect for TMDX
Per a report by Zion Market Research, the global organ transplantation market size was worth around $18.59 billion in 2023 and is predicted to grow to around $33.32 billion by 2032, at a CAGR of roughly 6.70%.
The organ transplantation market is growing as rising cases of chronic diseases increase the need for transplants, while advances in immunosuppression therapies improve patient outcomes and confidence in surgery. At the same time, innovations in organ preservation technologies are extending organ viability and boosting transplant success rates, supporting broader adoption.
Other News
In January, TMDX announced a long-term lease for its new global headquarters at Assembly Innovation Park and acquired adjacent land to build an integrated campus, underscoring its commitment to accelerating innovation, growth, and the transformation of organ transplant therapy.
TMDX’s Zacks Rank & Stocks to Consider
TMDX carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , GE HealthCare Technologies (GEHC - Free Report) and AtriCure (ATRC - Free Report) .
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.8% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 13.2%.
GE HealthCare Technologies, currently carrying a Zacks Rank #2 (Buy), reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.
GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 13.4% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.
AtriCure, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted loss per share of 1 cent, narrower than the Zacks Consensus Estimate by 90.9%. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%.
ATRC has an estimated earnings growth rate of 91.7% for 2026 compared with the industry’s 16.5% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.1%.